Psoriasis: A Primer for General Physicians

Area of Science:

• Immunodermatology
• Genetics
• Inflammation

Background:

• Psoriasis is a complex, polygenic inflammatory disease primarily affecting the skin.
• Genetic predisposition and environmental triggers, such as infections, contribute to disease onset.
• Key players in psoriasis pathogenesis include the Interleukin (IL)-23/IL-17 axis, immune cells like macrophages and dendritic cells (DCs), cytokines, and toll-like receptors.

Purpose of the Study:

• To summarize current topical and systemic therapies for psoriasis.
• To review the role of biological therapies, including TNF alpha inhibitors and IL-17/IL-23 inhibitors.
• To highlight emerging therapeutic strategies for psoriasis management.

Main Methods:

• Literature review of psoriasis pathogenesis and treatment modalities.
• Analysis of the immunopathogenesis involving cytokines and immune cells.
• Evaluation of existing and novel therapeutic interventions.

Main Results:

• The IL-23/IL-17 axis is central to psoriasis pathogenesis.
• Biological therapies targeting TNF alpha, IL-17, and IL-23 have demonstrated efficacy.
• Emerging therapies include modulators of sphingosine 1-phosphate receptor 1 and Rho-associated kinase 2 inhibitors.

Conclusions:

• Psoriasis management involves a range of therapies, from topical to systemic biologics.
• Targeting specific immune pathways like IL-23/IL-17 is effective.
• Novel therapeutic targets offer future potential for improved psoriasis treatment.